Charleston Oncology | Charleston, NC

Research site

(Unclaimed)

Location

2085 Henry Tecklenburg Drive, 2nd Floor, Charleston, South Carolina, United States of America

Site insights

Top conditions

Top treatments

Pembrolizumab

Magrolimab

Daratumumab

Ipilimumab

Bevacizumab

AL101

Enzalutamide

Sunitinib

Oxaliplatin

Trastuzumab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 20 total trials

A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer (FRESCO-2)

This is a global, randomized, double-blind, placebo-controlled, multicenter phase 3 clinical trial to compare the efficacy and safety of fruquintinib...

Active, not recruiting

Metastatic Colorectal Cancer

Metastatic Colon Cancer

Drug: Fruquintinib

Drug: Placebo

A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10)

The goal of this study is to evaluate the efficacy and safety of pembrolizumab combined with carboplatin and paclitaxel as first-line treatment in pa...

Active, not recruiting

Squamous Cell Carcinoma of Head and Neck

Drug: Pembrolizumab

Drug: Paclitaxel

Locations recently updated

A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)

This study is being done to see if tucatinib works better than placebo when given with other drugs to treat participants with HER2-positive breast ca...

Active, not recruiting

HER2 Positive Breast Cancer

Drug: Pertuzumab

Drug: Trastuzumab

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL (ECHELON-3)

Participants in this study will have diffuse large B-cell lymphoma (DLBCL) that has come back or not gotten better with treatment. The trial will stu...

Active, not recruiting

Diffuse Large B-cell Lymphoma

Drug: Rituximab

Drug: Lenalidomide

Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies

The purpose of this study is to evaluate the antitumor effects of sotorasib and RMC-4630 in subjects with KRASG12C mutant NSCLC

Active, not recruiting

Non-Small Cell Lung Cancer

Drug: RMC-4630

Drug: Sotorasib

Locations recently updated

Pan Tumor Rollover Study

Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tum...

Enrolling

Cancer

Drug: Temozolomide

Drug: Capecitabine

Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer (ELEVATE TNBC)

The goals of this clinical study are to learn about the safety, tolerability, dosing and effectiveness of magrolimab in combination with nab-paclitax...

Active, not recruiting

Triple-Negative Breast Cancer

Drug: Sacituzumab Govitecan-hziy

Drug: Magrolimab

Study of Magrolimab in Patients With Solid Tumors (ELEVATELung&UC)

The goals of this clinical study are to learn about the safety, tolerability, dosing and effectiveness of magrolimab in combination with docetaxel in...

Active, not recruiting

Solid Tumor

Drug: Magrolimab

Drug: Docetaxel

Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)

The primary hypothesis is that pembrolizumab/vibostolimab (MK-7684A) in combination with chemotherapy is superior to pembrolizumab in combination wit...

Active, not recruiting

Metastatic Non-Small Cell Lung Cancer

Biological: Pembrolizumab

Drug: Cisplatin

Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

A Phase 3 Study to Compare AMG 510 with Docetaxel in Non Small Cell Lung Cancer (NSCLC) subjects with KRAS p. G12c mutation

Active, not recruiting

KRAS p, G12c Mutated /Advanced Metastatic NSCLC

Drug: Docetaxel

Drug: AMG 510

Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer

The aim of this study is to provide darolutamide treatment to patients who participated in a previous study with darolutamide supported by Bayer and...

Enrolling

Cancer

Drug: Darolutamide (Nubeqa, BAY1841788)